Protalix BioTherapeutics
PLX
28 hedge funds and large institutions have $19.8M invested in Protalix BioTherapeutics in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.
9,467% more call options, than puts
Call options by funds: $1.15M | Put options by funds: $12K
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
47% more funds holding
Funds holding: 19 → 28 (+9)
41% more capital invested
Capital invested by funds: $14.1M → $19.8M (+$5.71M)
24.21% less ownership
Funds ownership: 40.43% → 16.22% (-24%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$2.3M |
| 2 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$644K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$594K |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$347K |
| 5 |
EMG
ETF Managers Group
Summit,
New Jersey
|
+$321K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$8.25M |
| 2 |
SG Americas Securities
New York
|
-$53K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$20.4K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$12K |
| 5 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $1K | +$653 | +191 | +616% |
|
|
27
SG Americas Securities
New York
| – | -$53K | -22,500 | Closed |
|
|
28
Group One Trading
Chicago,
Illinois
| – | -$20.4K | -5,969 | Closed |
|
|
29
Victory Capital Management
San Antonio,
Texas
| – | -$12K | -5,140 | Closed |
|
|
CA
30
Clearstead Advisors
Cleveland,
Ohio
| – | -$1K | -500 | Closed |
|
31
JP Morgan Chase
New York
| – | +$342 | +100 | New |
|
PLX Hedge Fund Activity: Q2 2020 in Review
28 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2020, worth a combined $19.8M — up 41% from $14.1M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PLX positions and 5 closed out — a net gain of 9 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was UBS O'Connor, opening a new position worth an estimated $2.3M. The largest seller was Highbridge Capital Management, cutting an estimated $8.25M.
- 28 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2020, up from 19 in Q1 2020.
- Funds reported $19.8M of Protalix BioTherapeutics stock for Q2 2020, up 41% quarter-over-quarter.
- 14 funds opened new Protalix BioTherapeutics positions in Q2 2020 and 5 closed out, a net change of +9 holders.
- The largest Protalix BioTherapeutics buyer in Q2 2020 was UBS O'Connor, an estimated $2.3M added.
- The largest Protalix BioTherapeutics seller in Q2 2020 was Highbridge Capital Management, an estimated $8.25M sold.
Based on aggregated 13F filings for Q2 2020.